JP2020507342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507342A5 JP2020507342A5 JP2019564394A JP2019564394A JP2020507342A5 JP 2020507342 A5 JP2020507342 A5 JP 2020507342A5 JP 2019564394 A JP2019564394 A JP 2019564394A JP 2019564394 A JP2019564394 A JP 2019564394A JP 2020507342 A5 JP2020507342 A5 JP 2020507342A5
- Authority
- JP
- Japan
- Prior art keywords
- target site
- repair template
- donor repair
- dna donor
- homologous arm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004414 DNA Proteins 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 35
- 101710163270 Nuclease Proteins 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000013603 viral vector Substances 0.000 claims description 23
- 108700019146 Transgenes Proteins 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 12
- 230000007017 scission Effects 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 102000002698 KIR Receptors Human genes 0.000 claims description 4
- 108010043610 KIR Receptors Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 3
- 101710092458 Lymphocyte activation gene 3 protein Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 7
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 108010083359 Antigen Receptors Proteins 0.000 description 5
- 102000006306 Antigen Receptors Human genes 0.000 description 5
- 230000000091 immunopotentiator Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 4
- 102100037935 Polyubiquitin-C Human genes 0.000 description 4
- 102000009572 RNA Polymerase II Human genes 0.000 description 4
- 108010009460 RNA Polymerase II Proteins 0.000 description 4
- 108010056354 Ubiquitin C Proteins 0.000 description 4
- 102000018146 globin Human genes 0.000 description 4
- 108060003196 globin Proteins 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- -1 ZFNs Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 101100162704 Emericella nidulans I-AniI gene Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 2
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 102000053200 Von Hippel-Lindau Tumor Suppressor Human genes 0.000 description 2
- 108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 2
- 208000005980 beta thalassemia Diseases 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 102100026792 Aryl hydrocarbon receptor Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100039894 Hemoglobin subunit delta Human genes 0.000 description 1
- 108091005903 Hemoglobin subunit delta Proteins 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 description 1
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001046587 Homo sapiens Krueppel-like factor 1 Proteins 0.000 description 1
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
- 101000642517 Homo sapiens Transcription factor SOX-6 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100022248 Krueppel-like factor 1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102220562136 Putative uncharacterized protein encoded by HEXA-AS1_E22A_mutation Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100036694 Transcription factor SOX-6 Human genes 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102220005330 rs34956202 Human genes 0.000 description 1
- 102220149336 rs886059922 Human genes 0.000 description 1
- 108010022404 serum-glucocorticoid regulated kinase Proteins 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459203P | 2017-02-15 | 2017-02-15 | |
| US62/459,203 | 2017-02-15 | ||
| PCT/US2018/018370 WO2018152325A1 (en) | 2017-02-15 | 2018-02-15 | Donor repair templates multiplex genome editing |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020507342A JP2020507342A (ja) | 2020-03-12 |
| JP2020507342A5 true JP2020507342A5 (enExample) | 2021-03-25 |
| JPWO2018152325A5 JPWO2018152325A5 (enExample) | 2022-10-17 |
| JP7236398B2 JP7236398B2 (ja) | 2023-03-09 |
Family
ID=63170730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564394A Active JP7236398B2 (ja) | 2017-02-15 | 2018-02-15 | ドナー修復鋳型多重ゲノム編集 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11499149B2 (enExample) |
| EP (2) | EP3583203B1 (enExample) |
| JP (1) | JP7236398B2 (enExample) |
| CN (1) | CN110446781A (enExample) |
| AU (1) | AU2018221730B2 (enExample) |
| CA (1) | CA3053499A1 (enExample) |
| DK (1) | DK3583203T5 (enExample) |
| ES (1) | ES2969213T3 (enExample) |
| WO (1) | WO2018152325A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| AU2015342749B2 (en) | 2014-11-07 | 2022-01-27 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
| WO2017053879A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| EP3848459A1 (en) | 2017-06-30 | 2021-07-14 | Inscripta, Inc. | Automated cell processing methods, modules, instruments and systems |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3781193A4 (en) | 2018-04-18 | 2022-01-26 | Altius Institute For Biomedical Sciences | Animal pathogen-derived polypeptides and uses thereof for genetic engineering |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| US12264181B2 (en) | 2018-06-27 | 2025-04-01 | Altius Institute For Biomedical Sciences | Nucleic acid binding domains and methods of use thereof |
| WO2020005383A1 (en) | 2018-06-30 | 2020-01-02 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| KR20210091167A (ko) | 2018-10-16 | 2021-07-21 | 블루알렐, 엘엘씨 | 유전자에서 dna의 표적화 삽입을 위한 방법 |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| US20230066806A1 (en) * | 2019-03-14 | 2023-03-02 | The Regents Of The University Of California | Pooled knock-in screening and heterologous polypeptides co-expressed under the control of endogenous loci |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| US10815467B2 (en) | 2019-03-25 | 2020-10-27 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| AU2020288623A1 (en) | 2019-06-06 | 2022-01-06 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| CN110358792A (zh) * | 2019-07-19 | 2019-10-22 | 华中农业大学 | 外源基因定点整合至actb基因下游的打靶载体构建方法及其应用 |
| WO2021102059A1 (en) | 2019-11-19 | 2021-05-27 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| EP4069851A4 (en) | 2019-12-18 | 2023-11-22 | Inscripta, Inc. | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| CN115135370A (zh) | 2020-01-27 | 2022-09-30 | 因思科瑞普特公司 | 电穿孔模块和仪器 |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| EP4214314A4 (en) * | 2020-09-15 | 2024-10-16 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| EP4271802A4 (en) | 2021-01-04 | 2024-12-04 | Inscripta, Inc. | MAD-NUCLEASES |
| US11332742B1 (en) | 2021-01-07 | 2022-05-17 | Inscripta, Inc. | Mad nucleases |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN118401548A (zh) * | 2021-11-26 | 2024-07-26 | 伊蒙纽斯治疗有限公司 | 细胞表面上的结合结构域分子 |
| EP4493706A1 (en) * | 2022-03-14 | 2025-01-22 | The Regents Of The University Of California | Integration of large nucleic acids into genomes |
| CN116212022A (zh) * | 2022-12-19 | 2023-06-06 | 中国医学科学院医学生物学研究所 | 一种芳香烃受体基因AhR作为治疗靶点在制备抗HSV-1病毒药物中的应用 |
| CN118538425B (zh) * | 2024-06-06 | 2024-10-29 | 北京大学第一医院(北京大学第一临床医学院) | 一种vhl综合征肾癌的诊断模型及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| PL169576B1 (pl) | 1990-10-12 | 1996-08-30 | Max Planck Gesellschaft | Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5503022A (en) | 1993-01-25 | 1996-04-02 | Barone; Larry A. | Marine impeller tester |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| ATE452972T1 (de) | 2001-05-01 | 2010-01-15 | Ca Nat Research Council | Induzierbares expressionssystem in eukaryotischen zellen |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| CA2765488C (en) | 2009-06-30 | 2018-01-02 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| US9169492B2 (en) | 2010-02-05 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| EP2534173B1 (en) | 2010-02-08 | 2019-09-11 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| CN111676196A (zh) | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| CA2946881A1 (en) | 2014-04-28 | 2015-11-05 | Recombinetics, Inc. | Multiplex gene editing in swine |
| IL301900A (en) | 2014-11-21 | 2023-06-01 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
| EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| WO2016176690A2 (en) | 2015-04-30 | 2016-11-03 | The Trustees Of Columbia University In The City Of New York | Gene therapy for autosomal dominant diseases |
| GB2531454A (en) | 2016-01-10 | 2016-04-20 | Snipr Technologies Ltd | Recombinogenic nucleic acid strands in situ |
| EP3426690A4 (en) | 2016-03-11 | 2019-10-09 | Bluebird Bio, Inc. | GENOMEDITIZED IMMUNEFFECTOR CELLS |
| JP2019510503A (ja) | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| JP2019528691A (ja) | 2016-08-19 | 2019-10-17 | ブルーバード バイオ， インコーポレイテッド | ゲノム編集エンハンサー |
| KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
-
2018
- 2018-02-15 DK DK18755081.9T patent/DK3583203T5/da active
- 2018-02-15 EP EP18755081.9A patent/EP3583203B1/en active Active
- 2018-02-15 JP JP2019564394A patent/JP7236398B2/ja active Active
- 2018-02-15 EP EP23205250.6A patent/EP4317447A3/en active Pending
- 2018-02-15 CN CN201880020639.2A patent/CN110446781A/zh active Pending
- 2018-02-15 CA CA3053499A patent/CA3053499A1/en active Pending
- 2018-02-15 WO PCT/US2018/018370 patent/WO2018152325A1/en not_active Ceased
- 2018-02-15 ES ES18755081T patent/ES2969213T3/es active Active
- 2018-02-15 US US16/485,345 patent/US11499149B2/en active Active
- 2018-02-15 AU AU2018221730A patent/AU2018221730B2/en active Active
-
2022
- 2022-10-21 US US18/048,631 patent/US20230174967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507342A5 (enExample) | ||
| JP2019526268A5 (enExample) | ||
| JP2020521456A5 (enExample) | ||
| JP7553440B2 (ja) | 抗ｃｄ３３免疫細胞癌療法 | |
| Leung | Use of NK cell activity in cure by transplant | |
| JP2023015098A (ja) | 養子細胞療法において投薬するための方法および組成物 | |
| JP2019535240A5 (enExample) | ||
| US11999773B2 (en) | Anti-BCMA chimeric antigen receptors | |
| JP2022539248A (ja) | 組換えａｄ３５ベクター及び関連遺伝子治療改善 | |
| WO2019089884A2 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
| CN113366479A (zh) | 二聚化剂调节的免疫受体复合物 | |
| WO2021035170A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| Stärck et al. | Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell–derived T cells | |
| US20250333762A1 (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| CN111655720A (zh) | Nkg2d daric受体 | |
| CN111565737A (zh) | Daric白细胞介素受体 | |
| Ercilla-Rodriguez et al. | CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects | |
| CN114402079A (zh) | Cd123靶向免疫疗法 | |
| Bridge et al. | Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy | |
| Yu et al. | CAR NK cell therapy for solid tumors: Potential and challenges | |
| RU2019110065A (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
| RU2019141853A (ru) | Варианты, композиции и способы применения эндонуклеазы cblb | |
| Castellano Esparza | Development of CRISPR/Cas9 multi-edited cord blood-derived CAR NK cells to improve their persistence and antitumor potential against Multiple Myeloma | |
| Chiu | Natural Killer Cell Immune Engagers to Induce Optimal Anti-Tumor Activity | |
| De Santis et al. | Natural Killer Cell Receptors |